About Microchips Biotech
Microchips Biotech is a company based in Lexington (United States) founded in 1999 by David H Koch was acquired by Daré Bioscience in November 2019. Microchips Biotech has raised $118.61 million across 9 funding rounds from investors including Medtronic, Novartis and Teva Pharmaceuticals. The company has 10 employees. Microchips Biotech operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Lexington, United States
- Employees 10
- Founders David H Koch
- SectorsHealthcare
- Email••••••••
- Website microchipsbiotech.com
- Social LinkedIn X
- Acquired by Daré Bioscience (Nov 2019)
- Legal Name Microchips, Inc.
- Total Equity Funding$118.61M (USD)
in 9 rounds
- Latest Funding Round$18.65M (USD), Series E
Jun 2015
- InvestorsMedtronic
& 9 more
- Employee Count10
- Acquired byDaré Bioscience
(Nov 2019)
Funding Insights of Microchips Biotech
Microchips Biotech has successfully raised a total of $118.61M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $18.65 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $118.61M
- Total Rounds 9
- Last Round Series E — $18.65M
- First Round $16M
(Jun 2002)
- Investors Count 9
All 9 funding rounds of Microchips Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $18.65M | Series E | – | Polaris Partners, Flybridge Capital Partners | – |
| Jun 2015 | $18.65M | Series E | – | – | |
| Jan 2010 | $16.5M | Series D | – | InterWest Partners, Polaris Partners | – |
| Mar 2009 | $9.21M | Series C | – | – | – |
| Mar 2009 | $9.21M | Series D | – | – | – |
| Jan 2007 | $10.39M | Series C | – | – | – |
| Jul 2005 | $10M | Series C | – | – | – |
| Dec 2003 | $10M | Series B | – | – | – |
| Jun 2002 | $16M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Microchips Biotech
Microchips Biotech has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Novartis and Teva Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Early-stage tech startups are funded by Flybridge Capital Partners. | – | flybridge.com | New York, United States | |
Early-stage life sciences and tech focused VC firm funding companies in the US | – | intersouth.com | Durham, United States | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Direct secondary investments are made in private company shares. | – | saintscapital.com | Denver, United States | |
- | – | carecapital.com | - | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel | |
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | medtronic.com | Minneapolis, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Non-hormonal pharmaceutical products for female contraceptives are developed. | 2005 | darebioscience.com | San Diego, United States |
Investor details for Microchips Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Microchips Biotech
1 people are tracked at Microchips Biotech (1 in leadership); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
David H Koch | Co-Founder | Leadership |
Complete people profiles for Microchips Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Microchips Biotech
4 dated milestones of Microchips Biotech across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Microchips Biotech is founded.
- Funding First funding round of $16.0M.
- Funding Latest funding round, Series E, of $18.6M.
- Exit Acquired by Daré Bioscience.
Competitors of Microchips Biotech
Microchips Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Microchips Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Microchips Biotech
Complete news archive for Microchips Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Microchips Biotech
10 companies that operate in the same segment as Microchips Biotech (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Microchips Biotech
Microchips Biotech was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Microchips Biotech is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Microchips Biotech is a funded company, having raised a total of $118.61M across 9 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Jun 2002.
Microchips Biotech has 10 employees.
Microchips Biotech develops microchip implants for drug delivery. Its platform technology is an implantable microchip that can be inserted in a physicians office under local anesthesia and can be activated or inactivated wirelessly. This microchip can then release preset doses of the device over months and years. Microchips has won a grant from the Bill and Melinda Gates Foundation to use its platform technology to develop an implantable contraceptive device for women with a life of 16 years. In addition, the company has a partnership with Teva to apply its drug delivery platform for Teva generics in the management of chronic diseases, like osteoporosis. Microchips was co-founded by MITs Robert Langer and Michael Cima. The technology can be used for therapies that require frequent, long-term dosing, or delivery via injection in diseases such as osteoporosis, diabetes, multiple sclerosis, pain management and several others.
Microchips Biotech's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Microchips Biotech has 10 investors. Key investors include Medtronic, Novartis, Teva Pharmaceuticals, Daré Bioscience, and Polaris Partners.
Microchips Biotech operates through Microchips, Inc..
Yes. Microchips Biotech was acquired by Daré Bioscience in November 2019.